4565
Nxera Pharma Co.,Ltd.
ネクセラファーマ
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- IFRS
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Dec 2021
17,712
Dec 2022
15,569
Dec 2023
12,766
Dec 2024
28,835
Dec 2025
29,615
Operating profit(million JPY)
Dec 2021
3,775
Dec 2022
3,436
Dec 2023
-9,526
Dec 2024
-5,423
Dec 2025
-8,462
Operating profit margin(%)
Dec 2021
21.31
Dec 2022
22.07
Dec 2023
-74.62
Dec 2024
-18.81
Dec 2025
-28.57
Profit before tax(million JPY)
Dec 2021
433
Dec 2022
1,078
Dec 2023
-10,680
Dec 2024
-4,662
Dec 2025
-14,950
Profit(million JPY)
Dec 2021
1,017
Dec 2022
382
Dec 2023
-7,193
Dec 2024
-4,838
Dec 2025
-12,530
Total assets(million JPY)
Dec 2021
96,985
Dec 2022
99,417
Dec 2023
157,198
Dec 2024
151,498
Dec 2025
134,787
Cash and cash equivalents(million JPY)
Dec 2021
60,087
Dec 2022
66,557
Dec 2023
49,065
Dec 2024
32,268
Dec 2025
20,365
Cash flows from operating activities(million JPY)
Dec 2021
7,095
Dec 2022
9,952
Dec 2023
-5,273
Dec 2024
-7,718
Dec 2025
-2,668
Cash flows from investing activities(million JPY)
Dec 2021
278
Dec 2022
1,043
Dec 2023
-63,791
Dec 2024
-4,763
Dec 2025
5,430
Cash flows from financing activities(million JPY)
Dec 2021
11,123
Dec 2022
-4,887
Dec 2023
48,329
Dec 2024
-6,854
Dec 2025
-16,028
Return on equity(%)
Dec 2021
1.9
Dec 2022
0.7
Dec 2023
-11.5
Dec 2024
-7.2
Dec 2025
-19.3
Equity ratio(%)
Dec 2021
59.3
Dec 2022
58.3
Dec 2023
42.5
Dec 2024
45.2
Dec 2025
45.3
Earnings per share(JPY per share)
Dec 2021
12.53
Dec 2022
4.68
Dec 2023
-87.18
Dec 2024
-53.92
Dec 2025
-138.8
Net assets per share(JPY per share)
Dec 2021
704.97
Dec 2022
707.2
Dec 2023
746.92
Dec 2024
762.15
Dec 2025
674.04
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.